Medexus Pharmaceuticals Inc.
Underestimation
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| P/E |
7/10
|
15.77 | 31.48 | -49.92% | 15.77 | 0% |
| P/S |
|
0.2726 | 3.24 | -91.59% |
|
|
| P/BV |
|
1.02 | 3.36 | -69.75% |
|
|
| P/FCF |
|
0 | 21.26 | -100% |
|
|
| Ev/Ebitda |
|
5.21 | 9.95 | -47.69% |
|
|
| Ev/S |
|
0.6675 | 1.89 | -64.74% |
|
|
| Ev/FCF |
|
4.09 | 19.96 | -79.51% |
|
|
| E/P |
|
0 | 1.47 | -100% |
|
|
Efficiency
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Ebitda margin |
4/10
|
13.55 | 24.35 | -44.35% | 4.55 | +197.96% |
| ROE |
|
-0.8111 | 13.19 | -106.15% |
|
|
| ROA |
|
-0.135 | 6.14 | -102.2% |
|
|
| ROIC |
|
0 | 15.56 | -100% |
|
|
| ROS |
|
-0.1893 | 12.56 | -101.51% |
|
|
| ROCE |
|
37.82 | 14.36 | 163.39% |
|
|
Debt
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Debt/Ebitda |
4/10
|
3.41 | 6.21 | -45.16% | 2.5 | +36.14% |
| Nеt Debt/Ebitda |
|
3.05 | -5.72 | -153.24% |
|
|
| Debt/Ratio |
|
0.3204 | 0.2122 | 51% |
|
|
| Debt/Equity |
|
55.5 | 12.49 | 344.32% |
|
|
| Debt/Net Income |
|
-233.16 | 15.05 | -1648.84% |
|
|
Dividends
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Dividend yield |
0/10
|
0 | 1.76 | -100% | 0 | 0% |
| Number of years of dividend growth |
|
0 | 1.21 | -100% | ||
| DSI |
|
0 | 0.7783 | -100% |
|
|
| Average dividend growth |
|
0 | -269.81 | -100% |
|
|
| Average percentage for 5 years |
|
0 | 2.8 | -100% |
|
|
| Average percentage for payments |
|
0 | 246.79 | -100% |
|
|
| Difference from average difference in sector |
|
-1.76 |
Growth impulse
| Parameter | Grade | Value | Sector average | Difference with sector, % | ||
|---|---|---|---|---|---|---|
| Growth impulse Revenue in 5 years |
7/10
|
51.95 | 140.59 | -63.05% | ||
| Growth impulse Ebitda in 5 years |
|
9111.32 | 107.17 | 8401.74% | ||
| Growth impulse Net Income in 5 years |
|
-96.55 | 123.16 | -178.39% | ||
| Growth impulse FCF in 5 years |
|
-627.09 | 93.68 | -769.4% | ||
| Growth impulse EPS in 5 years |
|
-97.97 | 229.02 | -142.78% |
IP Score
4.03/10
